DiaSorin to Acquire Luminex for ~$1.8B

 DiaSorin to Acquire Luminex for ~$1.8B

DiaSorin to Acquire Luminex for ~$1.8B

Shots:

  • DiaSorin to acquire Luminex for $37.00/ share in an all-cash transaction, with 23% premium based on closing stock price of Luminex on 24 Feb, 2021, making a total equity value of $1.8B
  • The acquisition will boost DiaSorin’s presence in the molecular diagnostics space in the US with the addition of Luminex’s molecular diagnostics multiplexing technology and a portfolio
  • Additionally, the acquisition will accelerate Luminex technology and solutions’ penetration outside the US via DiaSorin’s commercial and geographical reach

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Liminex

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post